OV2PC52TJZNG5PW4JK4QPO2EU4

U.S. FDA lifts hold on Bluebird’s sickle cell disease therapy

Bluebird Bio Inc (BLUE.O) said on Monday that the U.S. health regulator had lifted a partial clinical hold on studies for its gene therapy to treat blood disorder sickle cell disease.
The U.S. Food and Drug Administration’s decision ends a year-long halt on future studies and a pause in enrollment for ongoing studies of lovo-cel after one case of persistent anemia in a patient.

[Read More…]

Tags: No tags